1. Home
  2. EOD vs ACIU Comparison

EOD vs ACIU Comparison

Compare EOD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Global Dividend Opportunity Fund of Beneficial Interest

EOD

Allspring Global Dividend Opportunity Fund of Beneficial Interest

HOLD

Current Price

$5.98

Market Cap

252.4M

Sector

Finance

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$3.50

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOD
ACIU
Founded
2007
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.4M
213.3M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
EOD
ACIU
Price
$5.98
$3.50
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
118.1K
389.4K
Earning Date
01-01-0001
11-04-2025
Dividend Yield
9.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,482,957.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$644.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.73
$1.43
52 Week High
$4.71
$4.00

Technical Indicators

Market Signals
Indicator
EOD
ACIU
Relative Strength Index (RSI) 57.79 55.11
Support Level $5.92 $3.32
Resistance Level $6.02 $3.80
Average True Range (ATR) 0.06 0.24
MACD 0.01 0.02
Stochastic Oscillator 77.50 56.34

Price Performance

Historical Comparison
EOD
ACIU

About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest

Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: